Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autolymphocyte therapy
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autolymphocyte therapy (ALT) is an adoptive immunotherapy approach developed by the National Cancer Institute (NCI) for the treatment of renal cell carcinoma (RCC). The process involves the collection of a patient's own peripheral blood lymphocytes via leukapheresis, which are then activated and expanded ex vivo using the anti-CD3 monoclonal antibody muromonab-CD3 and the cytokine aldesleukin (interleukin-2). These activated "therapeutic autologous lymphocytes" are subsequently re-infused into the patient, typically in an adjuvant setting following surgical resection of the primary tumor. The goal of the therapy is to enhance the host's immune response against residual micrometastatic disease. This specific protocol was evaluated in Phase II clinical trials (such as NCT00003145) to determine its efficacy in improving outcomes for patients with stage III or IV non-metastatic renal cell carcinoma.
- Other names
- therapeutic autologous lymphocytesadjuvant autolymphocyte therapyautologous lymphocyte therapy
Beyond the preview
Go deeper on autolymphocyte therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autolymphocyte therapy.